Daiwa analyst Narumi Nakagiri upgrades $Bristol-Myers Squibb (BMY.US)$ to a buy rating, and adjusts the target price from $54 to $65.
According to TipRanks data, the analyst has a success rate of 75.0% and a total average return of 12.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Bristol-Myers Squibb (BMY.US)$'s main analysts recently are as follows:
The unexpected update on the Phase 2 results of emraclidine by AbbVie has led to revisions in revenue projections. With emraclidine being excluded from projections and an increase in Cobenfy estimates for Bristol Myers, there is a 7% rise in total expected revenue for 2033. This revision, however, does not alter the general trajectory of revenue or earnings per share growth for the companies involved.
Analysts noted that pivotal Phase 2 data for a competing schizophrenia treatment did not meet statistical significance in demonstrating change from baseline in a key symptom scale. This underperformance was unexpected, especially considering the treatment was a major factor in a significant acquisition and was projected to bring in substantial sales while competing with an established product. While the long-term outlook for the established product may improve as a result, there are still immediate concerns regarding patent exclusivity.
The failure of a competing drug, Emraclidine, to demonstrate a statistically significant benefit at the primary endpoint in its Phase 2 studies, places Bristol's Cobenfy in a favorable position. Given the underwhelming results that may send rivals back to the drawing board, it's pivotal for Bristol to capitalize on the opportunity and successfully launch Cobenfy.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
大和证券分析师Narumi Nakagiri上调$施贵宝 (BMY.US)$至买入评级,并将目标价从54美元上调至65美元。
根据TipRanks数据显示,该分析师近一年总胜率为75.0%,总平均回报率为12.1%。
此外,综合报道,$施贵宝 (BMY.US)$近期主要分析师观点如下:
艾伯维公司关于emraclidine的第二阶段结果的意外更新导致了营业收入预测的修订。由于emraclidine被从预测中排除,并且对百时美施贵宝的Cobenfy估计有所增加,预计2033年的总营业收入增长了7%。然而,这一修订并没有改变相关公司的营业收入或每股收益增长的总体趋势。
分析师指出,一种竞争的精神分裂症治疗药物的关键第二阶段数据在关键症状尺度的基线变化中未达到统计显著性。这一不佳表现令人意外,特别是考虑到该治疗是一次重大收购中的一个重要因素,并预计将带来可观的销售收入,同时又与一种成熟产品竞争。虽然成熟产品的长期前景可能因此改善,但仍存在关于专利独占性方面的直接担忧。
竞争药物Emraclidine在其第二阶段研究中未能在主要终点上显示出统计学显著性,这使得百时美施贵宝的Cobenfy处于有利位置。考虑到结果不尽如人意,可能会迫使竞争对手重新考虑,百时美施贵宝必须抓住这一机会,成功推出Cobenfy。
提示:
TipRanks为独立第三方,提供金融分析师的分析数据,并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议,仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级,分析师星级代表分析师所有推荐的过往表现,通过分析师的总胜率和平均回报率综合计算得出,星星越多,则该分析师过往表现越优异,最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否,取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合,并根据评级变化对组合进行调整,在近一年中该投资组合所获得的回报率。